Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

[18F]THK-5351 PET Imaging Distinctively Demonstrates Neurodegenerative Changes in Progressive Supranuclear Palsy Concomitant with Cerebellar Ataxia Patient and Amyotrophic Lateral Sclerosis Patient; Case Reports
Aging, Dementia, and Behavioral Neurology
P10 - Poster Session 10 (5:30 PM-6:30 PM)
10-007
To describe two cases of progressive supranuclear palsy (PSP) and one case of amyotrophic lateral sclerosis (ALS), who underwent [18F]THK-5351-PET imaging. One PSP patient investigated the correlation between the clinicopathological findings and accumulation of [18F]THK-5351 on postmortem examination.

[18F]THK-5351-PET imaging was developed to detect tau depositions, although recent studies revealed that [18F]THK-5351 binds to monoamine oxidase B in astrocytes. Astrogliosis is considered to be the neurodegenerative process, thus [18F]THK-5351 may be a candidate of a biomarker of neurodegeneration.

Case reports.
Two PSP patients developed postural instability eventually fell frequently in the seventh decade of life and manifested cerebellar ataxia. Upon brain MRI, both midbrain and cerebellar atrophy were detected and the diagnosis of PSP concomitant with cerebellar ataxia was made. ALS patient developed progressive dementia in the seventh decade of life and muscle weakness in the limbs, dysarthria, and dysphagia were subsequently noted. Upon neurological and electrophysiological evaluation, the diagnosis of ALS with predominant upper-motor-neuron involvement was made. Low β-amyloid 42 levels and high total- and phosphorylated-tau levels in the cerebrospinal fluid and accumulation of [11C]PiB in the cerebral cortex suggested the diagnosis of comorbid Alzheimer's disease (AD) in this patient. In PSP patients, increased accumulation of [18F]THK-5351 in the dentate nucleus of the cerebellum, as well as the midbrain, globus pallidum, and frontal lobe were detected. Postmortem examination performed seven years after the onset in one PSP patient revealed that tau pathology accompanied by gliosis was marked in the dentate nucleus and white matter in the cerebellum as well as in the midbrain, subthalamic nucleus, and globus pallidum. In ALS patient comorbid AD, [18F]THK-5351 markedly accumulated in the bilateral precentral gyrus and temporal lobe, reflecting neurodegeneration associated with both ALS and AD, respectively.

[18F]THK-5351 should be a useful biomarker that distinctively demonstrates specific neurodegenerative changes in affected brain.

Authors/Disclosures
Yuji Saitoh, MD, FÂé¶¹´«Ã½Ó³»­ (Tokyo Metropolitan Neurological Hospital)
PRESENTER
Dr. Saitoh has received stock or an ownership interest from Meiji Holdings Co. Ltd.. Dr. Saitoh has received stock or an ownership interest from Daiichi Sankyo Co. Ltd.. Dr. Saitoh has received stock or an ownership interest from Japan Tobacco Inc.. Dr. Saitoh has received stock or an ownership interest from Otsuka Holdings Co., Ltd.. Dr. Saitoh has received stock or an ownership interest from Fujifilm Holdings Corporation. Dr. Saitoh has received stock or an ownership interest from Johnson & Johnson. Dr. Saitoh has received stock or an ownership interest from 3M Company. The institution of Dr. Saitoh has received research support from Japan Agency for Medical Research and Development (AMED). Dr. Saitoh has received publishing royalties from a publication relating to health care. Dr. Saitoh has received publishing royalties from a publication relating to health care. Dr. Saitoh has received publishing royalties from a publication relating to health care.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Yuji Takahashi, MD, PhD (National Center of Neurology and Psychiatry) The institution of Dr. Takahashi has received research support from Nihon Medi-Physics Co. Limit.. The institution of Dr. Takahashi has received research support from Takeda Pharmaceutical Company Limited.